Commonly prescribed heart medications, including statins and diuretics, do not negatively affect the survival of ...

Application supported by Phase 3 data reinforcing teclistamab regimens as a potential standard of care after at least one prior therapy1 ...

On Thursday, the U.S. Food and Drug Administration approved Johnson & Johnson‘s JNJ Tecvayli in combination with Darzalex ...

SHARJAH, 16th March, 2026 (WAM) -- A new scientific study conducted by a research team at the University of Sharjah (UoS) has found that commonly prescribed cardiovascular medications, such as blood ...

The approval was supported by data from the ongoing Phase III MajesTEC-3 study.

Serious side effects, including neurotoxicity and intestinal inflammation, that appear weeks or months after patients receive CAR T cell therapy for multiple myeloma share a common immune root cause, ...

Kyprolis is a type of medicine called a proteasome inhibitor. The proteasome is like the cell's "trash disposal" system. Proteasome inhibitors such as Kyprolis bind to and block the activity of the ...

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...

How Does Sarclisa Work in Multiple Myeloma? Sarclisa is a type of medicine called a monoclonal antibody that is also known as a targeted therapy or an immunotherapy. It works by targeting a specific ...

Staging is when a system is used to identify and describe how far a cancer has spread in your body. Knowing the stage of your multiple myeloma helps your physicians predict which treatments are most ...